(:ARNA)
Business Focus: N/A
Feb 23, 2022 04:05 pm ET
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.
Feb 17, 2022 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new emp
Feb 09, 2022 04:05 pm ET
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets.
Jan 19, 2022 08:00 am ET
Halper Sadeh LLP Investigates LEVL, GCP, SLRC, MIME, ARNA; Shareholders are Encouraged to Contact the Firm
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 18, 2022 08:19 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds APR, ZNGA, BRG, and ARNA Shareholders About Its Ongoing Investigations
NEW YORK, Jan. 18, 2022 /PRNewswire/ --
Jan 18, 2022 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees. The inducement RSUs have a grant date and vesting commencement date of January 15, 2022 and were granted as inducements material to the new employees ente
Jan 14, 2022 10:23 pm ET
Investor Alert: The M&A Class Action Firm Continues Investigating the Merger - VG, TACO, ARNA, UMPQ, LEVL, NES
NEW YORK, Jan. 14, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 13, 2022 10:35 am ET
Halper Sadeh LLP Investigates BRG,FLMN, FLOW, ARNA; Shareholders are Encouraged to Contact the Firm
NEW YORK, Jan. 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 12, 2022 09:41 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds CSLT, TMX, ARNA, and MIME Shareholders About Its Ongoing Investigations
NEW YORK, Jan. 12, 2022 /PRNewswire/ --
Jan 08, 2022 03:44 pm ET
Halper Sadeh LLP Investigates FLOW, NEOG, ARNA, JUPW; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: SPX FLOW, Inc. (NYSE: FLOW) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
Jan 07, 2022 02:37 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds NEOG, SUNS, SEAC, and ARNA Shareholders About Its Ongoing Investigations
NEW YORK, Jan. 7, 2022 /PRNewswire/ --
Jan 05, 2022 01:02 pm ET
Halper Sadeh LLP Investigates STXB, GCP, ARNA, JUPW; Shareholders are Encouraged to Contact the Firm
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 04, 2022 09:05 pm ET
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - AR
NEW ORLEANS, Jan. 4, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Arena Pharmaceuticals, Inc. (Nasdaq GS: ARNA) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Arena will receive $100.00 in cash for each share of Arena that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 28, 2021 03:33 pm ET
Halper Sadeh LLP Investigates FLOW, TMX, NEOG, CCMP, ARNA; Shareholders are Encouraged to Contact the Firm
NEW YORK, Dec. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 25, 2021 12:02 am ET
Lifshitz Law Firm, P.C. Announces Investigation of ARNA, NEOG, FLOW, and TMX
Arena Pharmaceuticals, Inc. (NASDAQGS: ARNA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARNA to Pfizer Inc. for $100.00 in cash per share of ARNA owned. If you are an...
Dec 21, 2021 08:30 am ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of December 15, 2021 and were granted as inducements material to the new emp
Dec 20, 2021 02:08 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates VRS, GCP, ARNA, JUPW, MIME; Shareholders are Encouraged to Contact the Firm
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 20, 2021 10:48 am ET
Lifshitz Law Firm, P.C. Announces Investigation of ARNA, NEOG, FLOW, and TMX
Arena Pharmaceuticals, Inc. (NASDAQGS: ARNA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARNA to Pfizer Inc. for $100.00 in cash per share of ARNA owned. If you are an...
Dec 16, 2021 04:14 pm ET
Moore Kuehn Encourages NMMC, FLOW, ARNA, and GIIX Investors to Contact Law Firm
NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Dec 15, 2021 08:06 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of ARNA, NEOG, FLOW, and TMX
Arena Pharmaceuticals, Inc. (NASDAQGS: ARNA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARNA to Pfizer Inc. for $100.00 in cash per share of ARNA owned. If you are an...
Dec 15, 2021 05:04 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ARNA, JUPW, GCP, SLRC; Shareholders are Encouraged to Contact the Firm
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 14, 2021 10:25 pm ET
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - AR
NEW ORLEANS, Dec. 14, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Arena Pharmaceuticals, Inc. (Nasdaq GS: ARNA) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Arena will receive $100.00 in cash for each share of Arena that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 14, 2021 10:03 am ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Arena Pharmaceuticals Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating Arena Pharmaceuticals Inc. (“Arena”) (NASDAQ GS: ARNA) regarding possible breaches of fiduciary duties and other violations of law related to Arena’s agreement to be acquired by Pfizer Inc....
Dec 14, 2021 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ARNA, FLOW, GCP, TACO; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Dec 13, 2021 04:22 pm ET
Shareholder Alert: Ademi LLP investigates whether Arena Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Pfizer Inc.
MILWAUKEE, Dec. 13, 2021 /PRNewswire/ -- Ademi LLP is investigating Arena (Nasdaq: ARNA), for possible breaches of fiduciary duty and other violations of law in its transaction Pfizer.
Dec 13, 2021 04:15 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Arena Pharmaceuticals, Inc.
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arena Pharmaceuticals, Inc. ("Arena" or the "Company") (NASDAQ: ARNA), in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $100.00 per share in cash for each share of Arena common stock that they hold. The all-cash transaction is valued at approximately $6.7 billion.
Dec 13, 2021 12:25 pm ET
ARENA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARNA and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) breached their fiduciary duties or violated the...
Dec 13, 2021 10:00 am ET
Arena Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Arena Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARNA
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Pfizer Inc. for $100.00 per share in cash is fair to Arena shareholders.
Dec 13, 2021 07:35 am ET
Thinking about buying stock in Arena Pharmaceuticals, Bellus Health, Foghorn Therapeutics, Hexo Corp, or bluebird bio?
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARNA, BLU, FHTX, HEXO, and BLUE.
Dec 13, 2021 06:45 am ET
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the com
Nov 19, 2021 08:30 am ET
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved target enrollment in Study A of the Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate to severe Crohn's disease (CD). CULTIVATE Study A reached target enrollment of 70 study participants to assess etrasimod 2 mg and 3 mg in participants with CD.
Nov 16, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant da
Nov 04, 2021 04:05 pm ET
Arena Reports Third Quarter Financial Results and Key Program Updates
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
Oct 21, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options and inducement restricted stock units ("RSUs") to new employees. The inducement stock options and RSUs were approved by the Compensation Committee on October 5, 2021 and each have a grant da
Oct 14, 2021 04:05 pm ET
Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day
Sep 17, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant da
Sep 02, 2021 08:30 am ET
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s etrasimod programs. The Company will also participate in five upcoming investor conferences throughout September.
Aug 18, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs") to new employees. The inducement stock options, PRSUs, and RSUs each have a grant dat
Aug 05, 2021 04:05 pm ET
Arena Reports Second Quarter Financial Results and Key Program Updates
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
Aug 05, 2021 07:00 am ET
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
BRISBANE, Calif., Aug. 5, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod.
Jul 29, 2021 04:05 pm ET
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets. The Company will host a live webcast to discuss the results with the investment community the same day at 4:30 PM ET.
Jul 27, 2021 04:05 pm ET
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases.
Jul 22, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 45,200 shares of its common stock and 20,235 inducement restricted stock units ("RSUs"). The inducement stock options and RS
Jul 19, 2021 08:30 am ET
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, i
Jun 18, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 64,401 shares of its common stock and 27,857 inducement restricted stock units ("RSUs"). The inducement stock options and RS
Jun 14, 2021 08:30 am ET
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including b
Jun 09, 2021 08:43 am ET
Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).
Jun 08, 2021 08:30 am ET
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first participant has been randomized in a Phase 2 trial evaluating IV temanogrel, an investigational, peripherally acting, and selective 5-HT2A receptor inverse agonist, for the potential treatment of coronary microvascular obstruction (cMVO) in patients undergoing p
Jun 03, 2021 08:30 am ET
Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that as of 2021, Arena received an MSCI ESG Rating of "A." MSCI ESG Research provides MSCI ESG Ratings on global public and a few private companies on a scale of AAA (leader) to CCC (laggard), according to exposure to industry-specific ESG risks and the ability to manage those
May 19, 2021 05:30 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2021, the Compensation Committee of its Board of Directors granted to 22 new employees inducement stock options to purchase an aggregate of 74,905 shares of its common stock and 32,050 inducement restricted stock units ("RSUs"). The inducement stock options and RSU
May 12, 2021 08:30 am ET
Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it has been designated Prime in the ISS ESG Corporate Rating, effective as of May 4, 2021. Companies are classified as Prime when their ESG performance exceeds the threshold criteria for companies in its sector, meaning they fulfill ambitious absolute performance requirements.
May 05, 2021 04:05 pm ET
Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.
Apr 28, 2021 04:05 pm ET
Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at
Apr 23, 2021 10:10 am ET
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academ
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the
Apr 19, 2021 04:05 pm ET
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the release of its second annual ESG report, outlining the Company’s long-term commitment to the betterment of society, focusing on patients, our employees, the community, the environment, and shareholders. The report builds on Arena’s inaugural report and highlights specific d
Apr 19, 2021 08:30 am ET
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented during a late-breaking
Apr 16, 2021 06:35 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common stock and 20,490 inducement restricted stock units ("RSUs"). The inducement stock options and R
Mar 19, 2021 08:30 am ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units ("RSUs") to new employees. The inducement stock options, PRSUs, and RSUs each have a grant dat
Mar 02, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with ab
Feb 23, 2021 04:05 pm ET
Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020.
Feb 18, 2021 04:05 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common stock and 8,475 inducement restricted stock units ("RSUs"). The inducement stock options
Feb 16, 2021 04:05 pm ET
Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment communi
Feb 16, 2021 08:30 am ET
Arena Pharmaceuticals Announces Changes to Board of Directors
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member.
Feb 02, 2021 09:05 am ET
Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis
Jan 22, 2021 04:04 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common stock and 3,470 inducement restricted stock units ("RSUs"). The inducement stock options an
Dec 22, 2020 03:01 pm ET
Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:00 AM ET.
Dec 18, 2020 12:01 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common stock and 2,460 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of December 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5
Dec 11, 2020 08:00 am ET
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference.
Dec 08, 2020 07:30 am ET
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
SAN DIEGO, Dec. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved its targeted enrollment goal of 372 participants in the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of once-daily etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis.
Nov 30, 2020 04:05 pm ET
Arena Pharmaceuticals Announces R&D Leadership Transition
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced a transition of its R&D leadership and the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer reporting to Amit Munshi, President and CEO. The transition follows the retirement and resignation of Chris Cabell, M.D., M.H.S.
Nov 24, 2020 07:30 am ET
Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Tuesday, December 1, at 4:20 PM ET.
Nov 19, 2020 04:59 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to purchase an aggregate of 96,025 shares of its common stock and 17,590 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of November 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 563
Nov 09, 2020 03:05 pm ET
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
SAN DIEGO, Calif., Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.
Nov 09, 2020 03:01 pm ET
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to-severe atopic dermatitis (AD).
Nov 02, 2020 07:30 am ET
Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM ET.
Oct 28, 2020 08:30 am ET
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
SAN DIEGO, Oct. 28, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), and Longboard Pharmaceuticals, Inc., today announced the launch of Longboard Pharmaceuticals and the completion of a $56 million financing led by Farallon Capital Management, LLC, and other top tier healthcare investors, including Cormorant Asset Management, HBM Healthcare Investments, Highside Capital Management, and T. Rowe Price Associates, with participation from Arena. Longboard was previously a wholly-owned subsidiary of Arena and formerly known as Arena Neuroscience. Vincent Aurentz, Executive Vice Pr
Oct 20, 2020 04:01 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on October 15, 2020, the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock and 11,760 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of October 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 56
Aug 05, 2020 04:01 pm ET
Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter
SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.
Jul 29, 2020 04:01 pm ET
Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5
SAN DIEGO, July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET.
Jul 17, 2020 04:01 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 17, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 15, 2020, the Compensation Committee of its Board of Directors granted to six new employees inducement stock options to purchase an aggregate of 35,850 shares of its common stock and 6,310 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of July 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 18, 2020 04:01 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 80,250 shares of its common stock to 12 new employees and 12,360 inducement restricted stock units ("RSUs") to 11 new employees. The inducement stock options and RSUs have a grant date and vesting commencement date of June 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq List
Jun 15, 2020 08:30 am ET
Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
SAN DIEGO, June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global clinical development, health outcomes and medical affairs.
Jun 08, 2020 04:30 pm ET
Arena Pharmaceuticals Announces R&D Leadership Transition
SAN DIEGO, June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to its research and development leadership team. Effective June 9, 2020, Dr. Preston Klassen will be leaving the Company to pursue an opportunity as Chief Executive Officer of a San Diego-based private company, and Dr. Chris Cabell, Arena's Senior Vice President and Chief Medical Officer, will assume the role of Executive Vice President, Head of Research and Development, and Chief Medical Officer.
Jun 01, 2020 04:01 pm ET
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Arena. Including the option exercise, the aggregate gross proceeds to Arena from the offering were approximately $316.3 million, before deducting the underwriting discounts and commissi
May 28, 2020 08:30 am ET
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, May 28, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena. The gross proceeds from the offering are expected to be $275.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on June 1, 2020, subject to customary closing conditions. In addition, Arena has granted the underwriters of the offering a 30-day opt
May 27, 2020 04:01 pm ET
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, May 27, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena. In addition, Arena intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of th
May 26, 2020 08:30 am ET
Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
SAN DIEGO, May 26, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 2b ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis. The trial enrolled 140 patients at study sites across the United States, Canada and Australia, with a primary efficacy endpoint of percent change in Eczema Area and Severity Index (EASI) from baseline to week 12.
May 22, 2020 04:30 pm ET
Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SAN DIEGO, May 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Arena is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunitie
May 20, 2020 04:01 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 113,175 shares of its common stock to 13 new employees and 16,510 inducement restricted stock units ("RSUs") to ten new employees. The inducement stock options and RSUs have a grant date and vesting commencement date of May 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listi
May 19, 2020 04:10 pm ET
Galecto Appoints New Chair and Strengthens Board of Directors
Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its Board of Directors has appointed Amit Munshi as its new Chairman. Galecto also announced the...
May 13, 2020 04:01 pm ET
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences.
May 07, 2020 04:01 pm ET
Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
SAN DIEGO, May 7, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
May 06, 2020 08:30 am ET
Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13
SAN DIEGO, May 6, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Preston Klassen, MD, MHS, the Company's Executive Vice President, Head of Research & Development, is scheduled to participate in a virtual fireside chat at the Bank of America Securities 2020 Healthcare Conference on Wednesday, May 13, at 10:20 AM ET (7:20 AM PT).
Apr 30, 2020 08:30 am ET
Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7
SAN DIEGO, April 30, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET.
Apr 24, 2020 09:00 am ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 39,800 shares of its common stock to nine new employees and 1,320 inducement restricted stock units ("RSUs") to one new employee. The inducement stock options and RSUs have a grant date and vesting commencement date of April 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq
Apr 10, 2020 01:09 pm ET
Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14
SAN DIEGO, April 10, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, at 10:40 AM ET (7:40 AM PT).
Apr 01, 2020 04:01 pm ET
Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)
SAN DIEGO, April 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline data from a Phase 1 clinical study evaluating controlled-release delivery profiles (CR) for its investigational agent, etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator.
Mar 30, 2020 08:30 am ET
Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor
SAN DIEGO, March 30, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that James C. Mullen has agreed to serve as an independent senior advisor to the Company.
Mar 18, 2020 04:01 pm ET
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on March 12, 2020, the Compensation Committee of its Board of Directors approved inducement stock options and inducement performance restricted stock units ("PRSUs") to new employees that were granted as inducement material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). These grants include:
Nov 14, 2019 09:00 am ET
Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that...
Nov 07, 2019 03:01 pm ET
Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs
SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.
Nov 06, 2019 07:30 am ET
Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS
SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of etrasimod in healthy adult male volunteers. Etrasimod is an investigational next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator. The results were presented at the American Association of Pharmaceutical Scientists (AAPS) 2019 PHARMSCI 360 Meeting in San Antonio, Texas.
Nov 05, 2019 04:41 pm ET
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor conferences:
Oct 31, 2019 08:30 am ET
Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7
SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM EST.
Oct 28, 2019 08:30 am ET
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing
Oct 28, 2019 08:30 am ET
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing
Oct 22, 2019 04:01 pm ET
Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
SAN DIEGO, Calif., Oct. 22, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 25th Annual United European Gastroenterology (UEG) Week.
Oct 18, 2019 03:01 am ET
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community
SAN DIEGO, Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 25th Annual United European Gastroenterology (UEG) Week. Arena will also present data for olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in development for the treat
Sep 26, 2019 08:30 am ET
Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting
SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of immune-mediated and inflammatory conditions, including the ongoing ELEVATE UC Phase 3 trial that was initiated this year. These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey.
Sep 25, 2019 08:30 am ET
Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2
SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer of Arena, will present a corporate update at the Cantor Global Healthcare Conference on Wednesday, October 2, at 3:00 PM EDT. The conference will take place October 2-4, 2019, in New York City.
Sep 17, 2019 08:30 am ET
Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting
SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of immune-mediated and inflammatory conditions, including the expected initiation of a Phase 2 trial in atopic dermatitis later this year. These data will be presented at the 49th Annual European Society for Dermatologic Research (ESDR) Meeting. The meeting is taking place September 18-21, in Bordeaux, France.
Sep 09, 2019 08:30 am ET
Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting
SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting.
Aug 28, 2019 08:30 am ET
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences:
Aug 07, 2019 04:01 pm ET
Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.
Jul 31, 2019 08:30 am ET
Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
SAN DIEGO, July 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM EDT.
Jul 25, 2019 08:30 am ET
Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associated with Irritable Bowel Syndrome
SAN DIEGO, July 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the Phase 2 CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders. The trial will evaluate the efficacy and safety of three dose levels of olorinab for 12-weeks in approximately 240 subjects experiencing abdominal pain associated with IBS, including IBS with constipation (IBS-
May 21, 2019 07:30 am ET
Corvidia Therapeutics Announces Dr. Preston Klassen Joins its Board of Directors
WALTHAM, Mass., May 21, 2019 /PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage biotechnology company, today announced the appointment of Dr. Preston Klassen, M.D., M.H.S. to its Board of Directors.
May 17, 2019 08:30 am ET
Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community
SAN DIEGO, May 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC). Arena will present new data from its investigative drug candidates etrasimod, a next-generation, once-daily, oral, selective sphingosine 1 phosphate (S1P) receptor modulator, and olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB2) in development for the treatment of visceral p
May 13, 2019 08:30 am ET
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences:
May 08, 2019 04:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2019.
May 01, 2019 08:30 am ET
Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8
SAN DIEGO, May 1, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM EDT.
Apr 03, 2019 08:30 am ET
Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10
SAN DIEGO, April 3, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:00 PM EDT. The conference will take place April 9-10, 2019 in New York City.
Mar 26, 2019 07:30 am ET
New Research Coverage Highlights The Blackstone Group, Arena Pharmaceuticals, Arrow Electronics, AdvanSix, KBR, and RPM International — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of The Blackstone Group L.P. (NYSE:BX), Arena Pharmaceuticals, Inc....
Mar 08, 2019 07:30 am ET
Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
SAN DIEGO, March 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, at the 14th Congress of European Crohn's and Colitis
Feb 26, 2019 03:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2018.
Feb 21, 2019 07:30 am ET
Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:30 AM EST. The conference will take place February 27 – March 1, 2019 at the Lotte New York Palace in New York City.
Feb 20, 2019 03:01 pm ET
Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019, after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 p.m. EST.
Feb 07, 2019 03:30 pm ET
Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal diseases, at the Crohn's & Colitis Congress® in Las Vegas, NV.
Jan 30, 2019 07:55 am ET
Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental A
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cameco Corporation (NYSE:CCJ), American Equity Investment Life Holding...
Jan 24, 2019 07:00 pm ET
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
SAN DIEGO, Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH). The global license agreement for ralinepag was announced on November 15, 2018.
Jan 24, 2019 07:00 pm ET
United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag
RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Upon closing, United Therapeutics paid Arena
Jan 07, 2019 07:30 am ET
Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from the open-label extension (OLE) of the Phase 2 OASIS trial of its investigational drug candidate etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC). Overall, etrasimod demonstrated durable, long-term clinical remission and was generally safe and well tolerated in this trial.
Dec 19, 2018 07:30 am ET
Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO, Dec. 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 8:30 AM PST. The conference will take place January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco.
Dec 17, 2018 07:30 am ET
Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience in the life sciences industry.
Nov 27, 2018 07:35 am ET
Research Report Identifies Cheniere Energy Partners, LP, Arena Pharmaceuticals, Geron, Keysight Technologies, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and Casella Waste with Renewed Outlook
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cheniere Energy Partners, LP (NYSE:CQP), Arena Pharmaceuticals, Inc....
Nov 26, 2018 07:30 am ET
Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs
SAN DIEGO, Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointments of Robert Lisicki as Executive Vice President and Chief Commercial Officer, and Paul K. Audhya, MD, MBA, as Senior Vice President, Medical Affairs. Mr. Lisicki will report to Amit D. Munshi, Arena's President and Chief Executive Officer, and Dr. Audhya will report to Preston Klassen, MD, M.H.S., Executive Vice President, Research and Development and Chief Medical Officer. With these hires, Arena will be expanding its footprint into the Boston area.
Nov 20, 2018 07:30 am ET
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Calif., Nov. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences:
Nov 15, 2018 06:00 am ET
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and United Therapeutics Corporation (Nasdaq: UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).
Nov 13, 2018 07:30 am ET
Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018. APD418 is being developed to improve cardiac contractility with minimal effect on heart rate and blood pressure for decompensated heart failure (DHF).
Nov 07, 2018 03:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results
SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2018.
Oct 31, 2018 08:30 am ET
Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its third quarter 2018 financial results and provide a corporate update on Wednesday, November 7, 2018, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. EST.
Oct 15, 2018 09:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Meritor, Fred's, Arena Pharmaceuticals, AMERISAFE, Accelerate Diagnostics, and NextEra Energy — New Research Emphasizes Economic Gro
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Meritor, Inc. (NYSE:MTOR), Fred's, Inc. (NASDAQ:FRED), Arena...
Oct 08, 2018 04:01 pm ET
Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
SAN DIEGO, Oct. 8, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in ulcerative colitis (UC), were presented by Dr. William J. Sandborn at the American College of Gastroenterology Annual Meeting. The paper was awarded the 2018 ACG Auxiliary Award Recipient (Member).
Oct 02, 2018 08:00 am ET
Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
SAN DIEGO, Oct. 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from a planned interim analysis of the ongoing open-label extension of the Phase 2 trial of its investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).
Sep 24, 2018 04:01 pm ET
Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline results from its Phase 2a trial of olorinab, an investigational, peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of gastrointestinal pain.
Sep 21, 2018 09:15 am ET
Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds: etrasimod in inflammatory bowel disease (IBD), ralinepag in pulmonary arterial hypertension (PAH), and olorinab in visceral pain. The Company will also provide updates on its broader portfolio. The event will take place in New York City on Thursday, October 4, 2018, from 8-11:00 a.m. EDT.
Sep 20, 2018 08:30 am ET
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences:
Sep 17, 2018 08:30 am ET
Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with Crohn's disease, were presented at the International Association for the Study of Pain (IASP) World Congress in Boston, MA.
Aug 29, 2018 04:30 pm ET
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences:
Aug 28, 2018 01:54 pm ET
Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
SAN DIEGO, Aug. 28, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from two Phase 1 clinical studies evaluating an extended-release (XR) formulation of its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), were presented by Dr. John Adams, PhD at the European Society of Cardiology Congress on August 27.
Aug 14, 2018 08:25 am ET
New Research Coverage Highlights Arena Pharmaceuticals, Varian Medical, SS&C Technologies, Globus Medical, Zynga, and Diamondrock Hospitality — Consolidated Revenues, Company Growth, and Expectations
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Varian Medical Systems, Inc....
Aug 06, 2018 04:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2018.
Jul 30, 2018 04:30 pm ET
Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6
SAN DIEGO, July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. EDT.
Jul 10, 2018 08:30 am ET
Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
SAN DIEGO, July 10, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr. Gallahue is a highly accomplished executive with over 25 years of leadership experience in publicly-traded life sciences companies.
May 21, 2018 08:30 am ET
Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
SAN DIEGO, May 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the American Thoracic Society (ATS) International Conference on May 23. The meeting is taking place May 18-23 in San Diego, CA.
May 15, 2018 08:10 am ET
Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot Barn, and Green Dot — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Haemonetics Corporation (NYSE:HAE), Arena Pharmaceuticals, Inc....
May 10, 2018 08:30 am ET
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, May 10, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer, will present at the following investor conferences:
May 08, 2018 04:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN DIEGO, May 8, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2018.
May 02, 2018 08:30 am ET
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8
SAN DIEGO, May 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. EDT.
May 01, 2018 08:30 am ET
Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
SAN DIEGO and INDIANAPOLIS, May 1, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, and Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, today announced that they have entered into a licensing agreement to advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders. This compound, targeting an undisclosed G protein-coupled receptor (GPC
Apr 12, 2018 08:30 am ET
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
SAN DIEGO, April 12, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 2018 Annual Meeting on April 14. The meeting is taking place April 11-14 in Nice, France.
Mar 26, 2018 04:15 pm ET
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, March 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 9,775,000 shares of its common stock at a price to the public of $41.50 per share, including 1,275,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Arena. The gross proceeds from the offering were approximately $405.7 million, before deducting the underwriting discounts and commissions and offering expenses. Arena anticipates usin
Mar 23, 2018 07:30 pm ET
Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27
SAN DIEGO, March 23, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 3:00 p.m. EDT. The conference will take place March 27-28, 2018 at the Westin Grand Central Hotel in New York City.
Mar 21, 2018 07:07 pm ET
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, March 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share. All of the shares are being sold by Arena. The gross proceeds from the offering are expected to be approximately $352.8 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on March 26, 2018, subject to customary closing conditions. In addition, Arena has granted the underwriters a 30-day o
Mar 20, 2018 04:01 pm ET
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, March 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option to purchase up to an additional 1,125,000 shares of its common stock. All of the shares are being offered by Arena. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Mar 19, 2018 04:01 pm ET
Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
SAN DIEGO, March 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive topline Phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC). Patients receiving the 2 mg dose of etrasimod achieved statistically significant improvements versus placebo in the primary, all secondary, and clinical remission endpoints.
Mar 14, 2018 08:00 am ET
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
SAN DIEGO, March 14, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2017.
Mar 08, 2018 07:30 am ET
Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2017 Financial Results and Provide Corporate Update on Wednesday, March 14
SAN DIEGO, March 8, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018, before the open of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 8:30 a.m. EDT.
Mar 01, 2018 07:30 am ET
Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit
SAN DIEGO, March 1, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will present Phase 1 and preclinical data for the investigative drug candidate APD371 at the American Pain Society (APS) Annual Scientific Meeting on March 6.
Feb 16, 2018 07:30 am ET
Arena Pharmaceuticals Announces Changes to Board of Directors
SAN DIEGO, Feb. 16, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H. Bice, Phillip M. Schneider, and Christine A. White, M.D. have indicated that they will be retiring from the Board of Directors at the time of Arena's next annual stockholders' meeting, which is expected to held in June 2018.
Feb 06, 2018 03:30 pm ET
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that that members of its senior management team will present at two upcoming investor conferences in New York City.
Jan 31, 2018 07:40 am ET
Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Re
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliqua BioMedical, Inc. (NASDAQ:ALQA), Donegal Group,...
Jan 22, 2018 04:04 pm ET
Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on sphingosine-1-phosphate (S1P) receptor modulation in the treatment of autoimmune diseases in New York City on Monday, January 29, from 12-1:30 p.m. EST.
Dec 21, 2017 07:30 am ET
Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO, Dec. 21, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 2:30 p.m. PST. The conference will take place January 8-11, 2018, at the Westin St. Francis Hotel in San Francisco.
Nov 27, 2017 07:50 am ET
Market Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International — Emerging Consolidated Expect
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), National Fuel...
Nov 10, 2017 11:31 am ET
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis (UC). Etrasimod is an investigational-stage, oral, next-generation, sphingosine-1-phosphate (S1P) receptor modulator with improved pharmacology and pharmacokinetics intended for the treatment of autoimmune diseases. The study enrolled 157 patients at sites globally.
Nov 07, 2017 04:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results
SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today provided a corporate update and reported financial results for the third quarter ended September 30, 2017.
Oct 31, 2017 09:30 am ET
Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind, the Company's Executive Vice President and Chief Financial Officer, will present a corporate update at the 26th Annual Credit Suisse Healthcare Conference on Wednesday, November 8 at 12:10pm MST. The conference will take place November 6-8 at the Phoenician in Scottsdale, AZ.
Oct 30, 2017 09:30 am ET
Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7
SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2017 financial results and provide a corporate update on Tuesday, November 7, 2017, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. ET.
Oct 19, 2017 09:30 am ET
Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017
SAN DIEGO, Oct. 19, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that results of the Phase 2 clinical study of ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist, intended for the treatment of pulmonary arterial hypertension (PAH), will be presented at the American College of Chest Physicians 2017 (CHEST) Annual Meeting, taking place October 28 – November 1 at the Metro Toronto Convention Centre in Toronto, Canada.
Sep 06, 2017 09:30 am ET
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), at the 27th International Congress of the European Respiratory Society (ERS). ERS is taking place September 9-13, 2017 at the MiCo Milano Congressi in Milan, Italy.
Aug 29, 2017 09:30 am ET
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will participate in the following investor conferences in September:
Aug 22, 2017 09:30 am ET
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress
SAN DIEGO, Aug. 22, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on August 29 at the European Society of Cardiology Congress (ESC) 2017. ESC is taking place August 26 – 30 at the Fira Gran Via in Barcelona, Spain.
Aug 07, 2017 05:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 7, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today provided a corporate update and reported financial results for the second quarter ended June 30, 2017.
Jul 31, 2017 05:32 pm ET
Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2017 financial results and provide a corporate update on Monday, August 7, 2017, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. ET.
Jul 31, 2017 09:30 am ET
Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the underwriters of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share have exercised in full their option to purchase an additional 937,500 shares. All of the shares sold in the offering were offered by Arena. Total gross proceeds from the offering of an aggregate of 7,187,500 shares were $172.5 million, before deducting the underwriting discounts and commissions and offering expenses payable by Aren
Jul 12, 2017 09:11 pm ET
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, July 12, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share. All of the shares are being sold by Arena. The gross proceeds from the offering are expected to be $150.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on July 18, 2017, subject to customary closing conditions. In addition, Arena has granted the underwriters a 30‑day option to pur
Jul 11, 2017 05:05 pm ET
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, July 11, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option to purchase up to an additional $22.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arena. There can be no assurance as to whether or when the offering may be completed, or as
Jul 10, 2017 05:01 pm ET
Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension
SAN DIEGO, July 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH). In this 61-patient study, the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance (PVR) compared to placebo. Ralinepag also demonstrated numerical improvement in 6-minute walk distance (6MWD).
Jun 29, 2017 09:30 am ET
Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers
SAN DIEGO, June 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the completion of a Phase 1 comparative bioavailability study evaluating the pharmacokinetic (PK) profile of extended release (XR) ralinepag compared to the immediate release (IR) formulation in healthy adults.
Jun 15, 2017 09:30 am ET
Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference
SAN DIEGO, June 15, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 21, at 1:30 p.m. EDT. The conference will take place June 20-21, 2017, at the St. Regis in New York City.
Jun 14, 2017 05:01 pm ET
Arena Pharmaceuticals Announces Shareholders and Board of Directors Approve Reverse Stock Split
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that at the annual meeting of stockholders, held June 13, 2017, stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company's certificate of incorporation to effect a reverse stock split of Arena's outstanding common shares at an exchange ratio of 1-for-10, and a change in the number of authorized shares of common stock to 73.5 million shares. Arena's Board of Directors had previously directed that the proposal be submitted to the sharehold
Jun 14, 2017 09:30 am ET
Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors. Ms. Jarrett has over 20 years of experience as a senior executive and finance professional in the life sciences industry.
Jun 01, 2017 09:30 am ET
Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th
SAN DIEGO, June 1, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:30am EDT. The conference will take place June 6-9, 2017 at the Grand Hyatt New York in New York City.
May 18, 2017 09:30 am ET
Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
SAN DIEGO, May 18, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on the treatment of pulmonary arterial hypertension (PAH) in New York City on Thursday, May 25, from 8–9:30 a.m. EDT.
May 16, 2017 05:30 pm ET
Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
SAN DIEGO, May 16, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on May 23 at the American Thoracic Society (ATS) 2017 International Conference. The conference is taking place May 19-24 at the Walter E. Washington Convention Center in Washington, D.C.
May 09, 2017 05:01 pm ET
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results
SAN DIEGO, May 9, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today provided a corporate update and reported financial results for the first quarter ended March 31, 2017.
May 02, 2017 09:30 am ET
Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017
SAN DIEGO, May 2, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that the Company will release its first quarter 2017 financial results and provide a corporate update on Tuesday, May 9, 2017, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. ET.
Apr 21, 2017 05:01 pm ET
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, April 21, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000 shares of its common stock, including 9,000,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters. All of the shares were sold at a price to the public of $1.15 per share. Including the option exercise, the aggregate gross proceeds from the offering were approximately $79.4 million, before deducting the underwriting discounts and commissions and offering expenses
Apr 17, 2017 11:15 pm ET
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 60,000,000 shares of its common stock, offered at a price to the public of $1.15 per share. The gross proceeds from the offering are expected to be $69.0 million, before deducting the underwriting discounts and commissions and offering expenses payable by Arena. Arena has granted the underwriters a 30‑day option to purchase up to 9,000,000 additional shares of common stock. All of the shares are being offered by Arena. The offering is expec
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.